Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2017

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Japan Agreement are shown below (in thousands):

		Years Ended December 31,
Agreement	Deliverable	2017		2016		2015
Japan	License	$	1,310	$	3,465	$	1,024
	Milestones		—		10,000		—
	Total license and milestone revenue	$	1,310	$	13,465	$	1,024
	Collaboration services revenue*	$	64	$	166	$	198

When and if available compounds, manufacturing — clinical supplies and committee services have each been identified as separate units of accounting with standalone value and amounts allocable to these elements have been recognized and classified within the Collaboration services revenue line item within the consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through December 31, 2017		Deferred Revenue at December 31, 2017		Total Consideration Through December 31, 2017
License	$	47,020	$	—	$	47,020
When and if available compounds		25		24		49
Manufacturing--clinical supplies		2,180		—		2,180
Committee services		21		—		21
Total license and collaboration services revenue	$	49,246	$	24	$	49,270

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Years Ended December 31,
Agreement	Deliverable	2017		2016		2015
Europe	License	$	13,997	$	10,956	$	17,677
	Milestones		—		—		—
	Total license and milestone revenue	$	13,997	$	10,956	$	17,677
	Collaboration services revenue*	$	1,514	$	1,191	$	2,697

When and if available compounds, manufacturing — clinical supplies, development services — in progress at the time of signing of the agreement, and committee services have each been identified as a separate unit of accounting with standalone value and amounts allocable to these units have been recognized in revenue as services are performed and classified within the Collaboration services revenue line item within the consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through December 31, 2017		Deferred Revenue at December 31, 2017		Total Consideration Through December 31, 2017
License	$	426,270	$	—	$	426,270
When and if available compounds		423		388		811
Manufacturing--clinical supplies		10,210		—		10,210
Development services--in progress		34,153		—		34,153
Committee services		295		—		295
Total license and collaboration services revenue	$	471,351	$	388	$	471,739

U.S./RoW [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW and China Agreements were as follows (in thousands):

		Years Ended December 31,
Agreement	Deliverable	2017		2016		2015
U.S. / RoW and China	License	$	65,749	$	112,931	$	114,392
	Milestones		15,000		—		15,000
	Total license and milestone revenue	$	80,749	$	112,931	$	129,392
	Collaboration services revenue*	$	28,010	$	40,738	$	29,731
	China single unit of accounting**	$	—	$	—	$	—

Co-development, information sharing, and committee services have been combined into a single unit of accounting because the requirements to share information and serve on committees are useful only in combination with the development services, and because all three items are delivered over the same period while manufacturing — clinical supplies has been identified as a separate unit of accounting with standalone value and amounts allocable to this unit of accounting have been recognized and classified within the Collaboration services revenue line item within the consolidated statements of operations.

All revenues attributable to the China unit of accounting are deferred until all deliverables are met. The China license and collaboration services elements have been combined into a single unit of accounting and consideration allocable to this unit is being deferred due to FibroGen’s retention of manufacturing rights and lack of standalone value.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the U.S./RoW and China Agreements, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through December 31, 2017		Deferred Revenue at December 31, 2017		Total Consideration Through December 31, 2017
License	$	468,446	$	—	$	468,446
Co-development, information sharing & committee services		118,679		23,744		142,423
Manufacturing--clinical supplies		463		24		487
China-single unit of accounting		—		96,019		96,019
Total license and collaboration services revenue	$	587,588	$	119,787	$	707,375